LONDON, Nov. 28, 2017 /PRNewswire/ — Innovus Pharma, Plethora Solutions, Absorption Pharmaceuticals and Allergan are the leading companies dominating the premature ejaculation market. The global premature ejaculation (PE) market is expected to cross $1.9 billion, growing impressively at a CAGR of 8.9% during the period 2016?2022. A high burden of PE prevalence and associated chronic condition, which can, in turn, poses as a high-risk factor for the occurrence of this disease is the key market driver for the premature ejaculation market in both developing and developed countries. Regionally, the US is the main contributor to the global PE market. Despite the absence of PE drug in the US, the market in North America retains dominant share because of wide accessibility to PE off-labels and OTC drugs. In terms of route of administration, the oral drugs segment contributes a dominant share of nearly three-fourths of the global market.
Download the full report: https://www.reportbuyer.com/product/5219025
Base Year: 2016
Forecast Year: 2017?2022
Major vendors profiled in the report are as following:
Other prominent vendors include Menarini, GlaxoSmithKline, Ixchelsis, Dong-A Pharmaceutical, NeuroHealing Pharmaceuticals.
Scope of the Report
The report considers the present scenario of the global premature ejaculation market and its in-depth analysis for the period 2017–2022. It includes a detailed study of growth drivers, trends, and restraints. The report also profiles the leading vendors in the market and other key vendors.
The report provides the analysis of key segments of the market by route administration, mechanism of action, geography, and vendors. It provides a detailed analysis of revenue from various segments:
Mechanism of Action
Major trends, drivers, and restraints for each geography are included in the report.
Premature ejaculation (PE) is a male sexual dysfunction, which is characterized by the inability to delay ejaculation for more than one minute after penetration or sexual stimulation. The condition is associated with uncontrolled ejaculation either before or shortly after sexual penetration, or with minimal sexual stimulation.
The global premature ejaculation market is expected to cross $1.9 billion, growing impressively at a CAGR of 8.9% during the period 2016?2022. Increasing disease awareness, growing patient willingness to seek pharmaceutical therapy assistance for disease management and increasing presence of favorable guidelines, which recommended the use of drugs as first-line therapy for treatment of PE, will augment market prospects during the forecast period.
The report provides a holistic view of the global premature ejaculation market, the companies involved in the market, and